StemCells Therapy

16 May 2012 Angel Biotechnology Holdings plc (“Angel” or “the Company”) Angel signs new contract with ReNeuron to provide GMP (KOSDAQ: 018290.KQ – news) cell manufacturing services for completion of stroke clinical trial Angel Biotechnology Holdings plc, (AIM:ABH), the biopharmaceutical contract manufacturer, has signed a new contract with ReNeuron Group (Berlin: RQE.BE – news) plc (AIM:RENE) to perform GMP manufacturing services in support of the final part of the PISCES Phase 1 clinical trial of its ReN001 stem cell therapy for stroke; the value of the contract was not disclosed.

SAN DIEGO, May 14, 2012 /PRNewswire/ –Orexigen Therapeutics, Inc.

NOVATO, Calif., May 14, 2012 (GLOBE NEWSWIRE) — Raptor Pharmaceutical Corp. (“Raptor” or the “Company”) (Nasdaq:RPTP – News), announced that NASDAQ is adding Raptor to the NASDAQ Biotechnology Index (NASDAQ: NBI and XNBI)

PLEASANTON, Calif.–(BUSINESS WIRE)– IntegenX Inc., a privately held company and leading developer of rapid human DNA identification technology, DNA sequencing library preparation systems, and DNA/RNA room temperature stability and storage products, today announced the appointment of David V. Smith as Chief Operating Officer. David V

Biotechnology Information Organization (BIO): WHAT: WHO: Jim Greenwood, President and CEO, Biotechnology Information Organization (BIO); Ryan Stroschein, Co-Director, Agriculture Energy Coalition; Jerry Taylor, President, MFA Oil; Gary Haer, Chairman, National Biodiesel Board; Steve Reinford, Owner, Reinford Farms. WHEN: WHERE:

NEEDHAM, Mass.–(BUSINESS WIRE)– Celldex Therapeutics, Inc.

CAMBRIDGE, Mass.–(BUSINESS WIRE)– Infinity Pharmaceuticals, Inc. (NASDAQ: INFI – News) today announced that the company will be added to the NASDAQ Biotechnology Index (NBI). The semi-annual re-ranking of the index will become effective prior to market open on Monday, May 21, 2012

Background: One of the crucial factors for a sustainable and economical production of lignocellulosic based bioethanol is the availability of a robust fermenting microorganism with high tolerance to inhibitors generated during the pretreatment of lignocellulosic raw materials, since these inhibitors are known to severely hinder growth and fermentation. Results: A long-term adaptation in repetitive batch [...]

Background: The microbial bioemulsifiers was surface active compounds, are more effective in stabilizing oil-in-water emulsions. The yeasts have been isolated to produce bioemulsifiers from vegetable oils and industrial wastes. Results: Trichosporon mycotoxinivorans CLA2 is bioemulsifier-producing yeast strain isolated from effluents of the dairy industry, with ability to emulsify different hydrophobic substrates. Bioemulsifier production (mg/L) and [...]

Background: Industrial production of biofuels and other products by cellulolytic microorganisms is of interest but hindered by the nascent state of genetic tools. Although a genetic system for Clostridium thermocellum DSM1313 has recently been developed, available methods achieve relatively low efficiency and similar plasmids can transform C. thermocellum at dramatically different efficiencies. Results: We report [...]

Background: beta-Glucosidase is an important component of the cellulase enzyme system. It does not only participate in cellulose degradation, it also plays an important role in hydrolyzing cellulose to fermentable glucose by relieving the inhibition of exoglucanase and endoglucanase from cellobiose. Therefore, the glucose-tolerant beta-glucosidase with high specific activity for cellobiose might be a potent [...]

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART, IN, INTO OR FROM THE UNITED STATES OF AMERICA (THE UNITED STATES OR U.S.), CANADA, JAPAN OR AUSTRALIA OR ANY OTHER JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION. MEDIA RELEASE-COMMUNIQUE AUX MEDIAS-MEDIENMITTEILUNG Cytos Biotechnology Ltd. raises an additional CHF 3.2 million via Rights Offering Schlieren (Zurich), Switzerland, May 10, 2012 – Cytos Biotechnology Ltd

10 May 2012 Angel Biotechnology Holdings plc (“Angel” or “the Group”) Acquisition of assets of biomaterial manufacturing business Launch of Angel Biomedical Limited Angel Biotechnology Holdings plc, (AIM:ABH), the biopharmaceutical contract manufacturer, is pleased to announce with immediate effect the acquisition of the assets of an established biomaterial and collagen manufacturing business, through its newly formed and wholly owned subsidiary, Angel Biomedical Ltd (ABL) (www.angelbiomedical.com). ABL has been formed to enable the Group to become an active service provider and manufacturer of collagen products in the medical device, in-vitro diagnostic and regenerative medicine markets

HuffPost’s QuickRead… Loading… HuffPost’s QuickRead..

NEW YORK A onetime powerful biotechnology financier who was among America’s wealthiest before a 1990s criminal fraud conviction pleaded guilty to fresh securities fraud charges Wednesday, admitting that his ban from acting as a securities broker or dealer didn’t stop him from plunging illegally back into the world of biotech companies. David Blech, 56, his head cast downward, pleaded guilty to two counts of securities fraud in U.S.

OTTAWA, ONTARIO–(Marketwire -05/08/12)- The best and brightest high-school students from across the country gathered in Ottawa today for Canada’s annual bioscience competition for youth. Speaking at the awards ceremony, the Honourable Diane Finley, Minister of Human Resources and Skills Development, congratulated all the competitors and highlighted recent federal support for youth. “Our government’s top priority is job creation and economic growth and we recognize that as the future workforce, Canadian youth have much to contribute to our country’s long-term prosperity.” said Minister Finley

JEFFERSON COUNTY, AR — For the second time in three months, an industry chooses to plant roots in Jefferson County. County leaders welcomed Vivione Tuesday.

Biotechnology Industry Organization (BIO): WHAT: WHO: WHEN: Thursday May 10, 1:00 p.m. to 2:00 p.m. EDT RSVP: About BIO BIO represents more than 1,100 biotechnology companies, academic institutions, state biotechnology centers and related organizations across the United States and in more than 30 other nations

Public release date: 8-May-2012 [ | E-mail | Share ] Contact: Kimberly Brown brownk@aaps.org 703-248-4772 American Association of Pharmaceutical Scientists WHO: American Association of Pharmaceutical Scientists (AAPS) WHAT: The 2012 AAPS National Biotechnology Conference (NBC) will gather scientists from industry, government, and academia for three days of educational offerings specifically geared toward the biotechnology sector of the pharmaceutical sciences. The conference kicks off with a brand new advanced Immunogenicity Training Course and two AAPS Workshops, transitions into the 2012 NBC programming, and concludes with three AAPS sponsored short courses

SEATTLE, May 7, 2012 (GLOBE NEWSWIRE) — Plandai Biotechnology, Inc., a producer of highly bioavailable plant extracts, today filed a Form 8-K with the Securities and Exchange Commission announcing that it has executed the final loan documents with the Land and Agriculture Bank of South Africa. The total amount of the loan is 100 million Rand (US $13 million). Plandai Chairman and Chief Executive Officer, Roger Duffield, commented, “Closing this loan is a significant milestone for Plandai because it provides us with the capital necessary to move immediately into production of our highly bioavailable Green Tea extract without causing any dilution to our shareholders.